Premature conclusions may harm good ideas

Soerdjbalie-Maikoe V, Pelger RC, Lycklama a Nijeholt GA, Arndt JW, Zwinderman AH, Bril H, et al. Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2004;31(7):958–63. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990;66 Suppl 5:1017–21. Sarikay I, Sarikaya A, Holder LE. The role of single photon emission computed tomography in bone imaging. Semin Nucl Med 2001;31(1):3–16. Savelli G, Chiti A, Grasselli G, Maccauro M, Rodari M, Bombardieri E. The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res 2000; 20(2B):1115–20. Sedonja I, Budihna NV. The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine. Clin Nucl Med 1999;24(6):407–13. Grob JC, Thiel J, Methlin G, Wolf P, Bollack C. Quantitative bone scan and bone metastases in prostatic cancer. Urol Int 1985;40(1):45–7. Rydh A, Ahlstrom KR, Larsson A, Johansson L, Damber JE, Tomic R, Hietala SO. Quantitative bone scintigraphy. A methodological evaluation in prostate cancer. Acta Radiol 2000;41(2):183–8. Sundkvist GM, Lilja B, Mattsson S. Age-related normal uptake of 99mTc-MDP in the lower spine. Nuklearmedizin 1997(2); 36:52–5. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000;164(4):1248–53. Heidenreich A. Bisphosphonates in the management of metastatic prostate cancer. Oncology 2003;65 Suppl 1:5–11.